

**Annex H: Indicative non-binding estimated quantities SLD**

<b>Estimated quantities in basic units (tablet, vial, sachet etc.), for the period 1st January 2021 to 31 December 2021</b>	
<b>SLDs and consumables*</b>	<b>Total estimates, rounded (in basic units)</b>
<b>Schedule n°1: WHO-RECOMMENDED GROUP A AND B MEDICINES</b>	
Levofloxacin 250mg (blister)	40 000 000
Levofloxacin 500mg (blister)	8 000 000
Levofloxacin 750mg (blister)	50 000
Moxifloxacin 400mg (blister)	5 000 000
Bedaquiline 100mg (container)	23 000 000
Linezolid 600mg (blister)	10 000 000
Cycloserine 250mg (blister)	46 000 000
Clofazimine 100mg (blister/container)	25 000 000
<b>Schedule n°2: WHO-RECOMMENDED GROUP C MEDICINES</b>	
Ethionamide 250mg (blister)	6 500 000
Delamanid 50mg (blister)	6 000 000
Prothionamide 250mg (blister)	7 000 000
PAS Acid 4g (sachet)	30 000
PAS Sodium 4g (sachet)	500 000
Amikacin 500mg (ampoule)	1 000 000
Streptomycin 1g (vial)	100 000
Pretomanid 200mg (container)	75 000
Imipenem 500mg + Cilastatin 500mg (vial)	400 000
Meropenem 1g (vial)	10 000
Amoxicillin / Clavulanic acid 500mg + 125mg (blister)	300 000
<b>Schedule n°3: PRODUCTS WITH UNCERTAIN DEMAND</b>	
Terizidone 250mg (blister)	**
Water for Injection 10mL (vial/ampoule)	**
Syringes with re-use prevention, Safety Box	**
Syringes with re-use and injury prevention, Safety Box	**
<b>Schedule n°4: PRODUCTS FOR PEDIATRIC M/XDR TB TREATMENT</b>	
Levofloxacin 100mg (blister) dispersible tablets	2 000 000
Moxifloxacin 100mg (blister) dispersible tablets	110 000
Bedaquiline 20mg (container)	**
Linezolid 100mg/5 ml (bottle)	**
Linezolid 150mg (blister/container)	**
Cycloserine 125mg (blister)	650 000
Clofazimine 50mg (blister/container)	700 000
Ethionamide 125mg (blister) dispersible tablets	152 000
Amoxicillin / Clavulanic acid 250 mg + 62.5 mg (bottle)	**

**Remarks:**

\*-For detailed product specifications please refer to the Annex B of the ITB document

\*\*- Insufficient demand information to generate volume estimates